Lilly slams Times over trials data charge

Lilly took a sharp tone in responding to a New York Times article that the company said “likely created a strong false impression with readers that Lilly suppresses data.”

The Times article, following on a New England Journal of Medicine piece, claimed that Lilly suppressed Prozac clinical trials data.

“Not only was the Times' story inaccurate when it comes to Prozac—the NEJM article didn't identify a single Prozac study as unpublished—but it also likely created a strong false impression with readers that Lilly suppresses data,” the company said in a news release, concluding: “We clearly have been transparent. The data is publicly available online; we've presented it to healthcare professionals at major medical meetings; and we published it—more than once—in peer-reviewed medical journals. And we remain committed to transparency. All of which we would have told The New York Times…if only they had called and asked.”
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters